Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 131

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Hypogonadal Men Nonresponders to the PDE5 Inhibitor Tadalafil Benefit from Normalization of Testosterone Levels with a 1% Hydroalcoholic Testosterone Gel in the Treatment of Erectile Dysfunction (TADTEST Study)

Buvat, Jacques, Montorsi, Francesco, Maggi, Mario, Porst, Hartmut, Kaipia, Antti, Colson, Marie Helène, Cuzin, Beatrice, Moncada, Ignacio, Martin-Morales, Antonio, Yassin, Aksam, Meuleman, Eric, Eardley, Ian, Dean, John Daniel, Shabsigh, Ridwan·2011·The Journal of Sexual Medicine
DOI 10.1111/j.1743-6109.2010.01956.x
Open this paper in CoChat — free account

Abstract

Introduction: Addition of testosterone (T) may improve the action of phosphodiesterase type 5 inhibitors (PDE5-Is) in patients with erectile dysfunction not responding to PDE5-Is with low or low-normal T levels. Aims: To confirm this add-on effect of T in men optimally treated with PDE5-Is and to specify the baseline T levels at which such an effect becomes significant. Methods: A multicenter, multinational, double-blind, placebo-controlled study of 173 men, 45–80 years, nonresponders to treatment with different PDE5-Is, with baseline total T levels ≤4 ng/mL or bioavailable T ≤ 1 ng/mL. Men were first treated with tadalafil 10 mg once a day (OAD) for 4 weeks; if not successful, they were randomized in a double-blind, placebo-controlled design to receive placebo or a 1% hydroalcoholic T gel (50 mg/5 g gel), to be increased to 10 mg T if results were clinically unsatisfactory. Main Outcomes Measures: Mean change from baseline in the Erectile Function Domain Score of the International Index of Erectile Function and rate of successful intercourses (Sexual Encounter Profile 3 question). Results: Erectile function progressively improved over a period of at least 12 weeks in both the placebo and T treatment groups. In the overall population with a mean baseline T level of 3.37 ± 1.48 ng/mL, no additional effect of T administration to men optimally treated with PDE5-Is was encountered. The differences between the T and placebo groups were significant for both criteria only in the men with baseline T ≤3 ng/mL. Conclusions: The maximal beneficial effects of OAD dosing with 10 mg tadalafil may occur only after as many as 12 weeks. Furthermore, addition of T to this PDE5-I regimen is beneficial, but only in hypogonadal men with baseline T levels ≤3 ng/mL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1743-6109.2010.01956.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 25

  1. Buvat, 2008, Combination therapy with phosphodiesterase type V inhibitors and testosterone., Current Sexual Health Reports, 5, 135, 10.1007/s11930-008-0024-7 · DOI
  2. Traish, 1999, Effects of castration and androgen replacement on erectile function in a rabbit model, Endocrinology, 140, 1861, 10.1210/endo.140.4.6655 · DOI · Paper page
  3. Morelli, 2004, Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa, Endocrinology, 145, 2253, 10.1210/en.2003-1699 · DOI · Paper page
  4. Zhang, 2005, Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum, Eur Urol, 47, 409, 10.1016/j.eururo.2004.10.021 · DOI
  5. Filippi, 2009, Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome, J Sex Med, 6, 3274, 10.1111/j.1743-6109.2009.01467.x · DOI · Paper page
  6. Guay, 2001, Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors, J Androl, 22, 793, 10.1002/j.1939-4640.2001.tb02582.x · DOI · Paper page
  7. Park, 2005, Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction, BJU Int, 95, 366, 10.1111/j.1464-410X.2005.05301.x · DOI
  8. Rosenthal, 2006, Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone, Urology, 67, 571, 10.1016/j.urology.2005.09.032 · DOI
  9. Koulikov, 2007, Is sildenafil citrate associated with an amelioration of the symptomatology of androgen decline in the aging male?, J Urol, 177, 2267, 10.1016/j.juro.2007.01.123 · DOI · Paper page
  10. Teloken, 2007, Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer, J Urol, 178, 2521, 10.1016/j.juro.2007.08.007 · DOI
  11. Shamloul, 2005, Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: A pilot study, J Sex Med, 2, 559, 10.1111/j.1743-6109.2005.00071.x · DOI · Paper page
  12. Hwang, 2006, Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone, Int J Impot Res, 18, 400, 10.1038/sj.ijir.3901446 · DOI · Paper page
  13. Yassin, 2006, Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: Results from an open-label uncontrolled study, Andrologia, 38, 61, 10.1111/j.1439-0272.2006.00712.x · DOI · Paper page
  14. Rochira, 2006, Sildenafil improves sleep-related erections in hypogonadal men: Evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections, J Androl, 27, 165, 10.2164/jandrol.05077 · DOI
  15. Tsertsvadze, 2009, Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis, Ann Intern Med, 151, 650, 10.7326/0003-4819-151-9-200911030-00150 · DOI
  16. McMahon, 2004, Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil, J Sex Med, 1, 292, 10.1111/j.1743-6109.04042.x · DOI · Paper page
  17. Rosen, 1997, The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 · DOI · Paper page
  18. Rosen, 2002, The International Index of Erectile Function (IIEF): A state-of-the-science review, Int J Impot Res, 14, 226, 10.1038/sj.ijir.3900857 · DOI · Paper page
  19. Shabsigh, 2006, The evolving role of testosterone in the treatment of erectile dysfunction, Int J Clin Pract, 60, 1087, 10.1111/j.1742-1241.2006.01101.x · DOI
  20. Bhasin, 2006, Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline, J Clin Endocrinol Metab, 91, 1995, 10.1210/jc.2005-2847 · DOI · Paper page
  21. Kaufman, 2005, The decline of androgen levels in elderly men and its clinical and therapeutic implications, Endocr Rev, 26, 833, 10.1210/er.2004-0013 · DOI · Paper page
  22. Aversa, 2004, Hormonal supplementation and erectile dysfunction, Eur Urol, 45, 535, 10.1016/j.eururo.2004.01.005 · DOI
  23. Buvat, 2006, Significance of hypogonadism in erectile dysfunction, World J Urol, 24, 657, 10.1007/s00345-006-0131-x · DOI
  24. Bruzziches, 2008, Redefining the role of long-acting phosphodiesterase inhibitor tadalafil in the treatment of diabetic erectile dysfunction, 4, 24
  25. Roumeguère, 2010, Effects of phosphodiesterase inhibitors on the inflammatory response of endothelial cells stimulated by myeloperoxidase-modified low-density lipoprotein or tumor necrosis factor alpha, Eur Urol, 57, 522, 10.1016/j.eururo.2009.01.030 · DOI

Cited by

See all 131

Metadata

Authors
Buvat, J., Montorsi, F., Maggi, M., Porst, H., Kaipia, A., Colson, M. H., Cuzin, B., Moncada, I., Martin-Morales, A., Yassin, A., Meuleman, E., Eardley, I., Dean, J. D., & Shabsigh, R.
Venue
The Journal of Sexual Medicine
Publisher
Oxford University Press (OUP)
Published
2011-01-01
Volume
8
Issue
1
Pages
284-293
ISSN
  • 1743-6109
  • 1743-6095
DOI
10.1111/j.1743-6109.2010.01956.x
Cited by
131
References
7
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.